

Tislelizumab RATIONALE 306

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



QoL data pending



**Serious and disabling adverse effects**



**Other adjustments**



Tislelizumab RATIONALE 306

### SCORE

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Tislelizumab, in combination with platinum-based chemotherapy, is indicated for the first-line treatment of adult patients with unresectable, locally advanced or metastatic OSCC whose tumours express PD-L1 with a tumour area positivity (TAP) score  $\geq 5\%$

Experimental Arm: Tislelizumab + Platinum + fluoropyrimidine or paclitaxel

Control Arm: Placebo + platinum + fluoropyrimidine or paclitaxel



